Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Bluejay Diagnostics, Inc. (BJDX)

Bluejay Diagnostics completes Toray manufacturing milestone ahead of Oct. 23 deadline

Neutral Impact 2 of 5 product/contract Written later

Bluejay Diagnostics said on October 13, 2026 that it has completed establishing a manufacturing site for Symphony cartridges, ahead of an October 23, 2026 contractual deadline under its amended license agreement with Toray Industries. The filing states the milestone is a step toward regulatory submission and potential commercialization, but it reports no revenue, earnings or guidance figures.

Key points

  • Milestone completed ahead of the October 23, 2026 deadline in the amended Toray Industries license agreement.
  • Manufacturing site is SanyoSeiko Co., Ltd. in Japan; ALURIS Sciences in the United States is a complementary manufacturing partner.
  • The Symphony IL-6 Test has not been cleared or approved by the FDA and is not available for commercial clinical use in the United States.
  • The filing contains no financial results, guidance or dollar figures.

The filing

CompanyBluejay Diagnostics, Inc. (BJDX)
Form8-K, current report
Filed with the SECOct 13, 2026, 9:09 AM ET
Accession number0001213900-26-108779

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.